Technical Analysis for EXMWW - Emmaus Life Sciences, Inc

Grade Last Price % Change Price Change
B 0.012 0.00% 0.0000
EXMWW closed unchanged on Friday, May 13, 2022, on 1.15 times normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A N/A

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Hot IPO Pullback Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Hot IPO Pullback Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Gapped Down Weakness 0.00%
Narrow Range Bar Range Contraction -50.00%
New 52 Week Closing High Bullish -50.00%
Narrow Range Bar Range Contraction -50.00%
New 52 Week High Strength -50.00%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Emmaus Life Sciences, Inc Description

Emmaus Life Sciences, Inc. is a biopharmaceutical company. The Company is engaged in discovery, development, marketing and sale of treatments and therapies, primarily for rare and orphan diseases. The Company’s lead product, Endari was approved by the United States Food and Drug Administration (FDA) to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari has received Orphan Drug designation from the FDA and Orphan Medicinal designation from the European Commission. Endari’s safety profile was like the placebo and Endari was well-tolerated in pediatric and adult patients alike. The most common occurring in more than 10% of patients treated with Endari were constipation, nausea, headache, abdominal pain, cough, pain in extremity, back pain, and chest pain. Its solution provides a safe and effective means for reducing the frequency of sickle cell crises in patients with SCD.


Classification

Keywords: Health Health Sciences Drugs Biopharmaceutical Pain Nausea Constipation Cough Headache Abdominal Pain Endari Orphan Drugs Rare And Orphan Diseases Sickle Cell Disease European Commission Pembrolizumab

Is EXMWW a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 0.024
52 Week Low 0.012
Average Volume 4,362
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 0.0000
10-Day Moving Average 0.0000
Average True Range 0.0000
RSI 0.00
ADX 0.0
+DI 0.0000
-DI 0.0000
Chandelier Exit (Long, 3 ATRs) N/A
Chandelier Exit (Short, 3 ATRs) N/A
Upper Bollinger Bands 0.0000
Lower Bollinger Band 0.0000
Percent B (%b) 0.0
BandWidth 0.0000
MACD Line 0.0000
MACD Signal Line 0.0000
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0120
Resistance 3 (R3) 0.0120 0.0120 0.0120
Resistance 2 (R2) 0.0120 0.0120 0.0120 0.0120
Resistance 1 (R1) 0.0120 0.0120 0.0120 0.0120 0.0120
Pivot Point 0.0120 0.0120 0.0120 0.0120 0.0120
Support 1 (S1) 0.0120 0.0120 0.0120 0.0120 0.0120
Support 2 (S2) 0.0120 0.0120 0.0120 0.0120
Support 3 (S3) 0.0120 0.0120 0.0120
Support 4 (S4) 0.0120